Case Studies

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...

Challenge: A former venture fund client identified a novel Phase 1-ready asset for treating a rare CNS infectious disease and was interested in licensing the asset and founding a new company to...

Challenge: A UK-based pharma company specializing in oncology drug development sought to understand the potential value of a nanoparticle drug product in small cell lung cancer (SCLC). Alacrita was...

Challenge: A private venture-backed US biotech company was developing a biologic through late-stage drug discovery and wished to quantify the commercial opportunity for the product in treating anemia...

Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory board (SAB) tasked...

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...

Project Challenge: A US technology transfer office required support in evaluating its life science research programs to help direct internal funding towards its most commercially viable projects....

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge: A national biomedical research agency requested Alacrita’s support with (1) a technical assessment of the agency’s own internal capabilities in AAV manufacturing, (2) a global landscape of...